Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding

New methods for detecting indications of neurodegeneration are necessary to diagnose neurodegenerative diseases. In identifying suitable biomarkers that can be monitored by these techniques, the pathogenic mechanisms that lead to these diseases may also be elucidated.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Current and future biomarkers for Alzheimer disease (AD).

References

  1. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Nat. Rev. Neurol. 6, 131–144 (2010).

    CAS  Article  Google Scholar 

  2. Savage, M.J. et al. J. Neurosci. 34, 2884–2897 (2014).

    CAS  Article  Google Scholar 

  3. Hölttä, M. et al. PLoS ONE 8, e66381 (2013).

    Article  Google Scholar 

  4. Yang, T. et al. Alzheimers Dement. 9, 99–112 (2013).

    Article  Google Scholar 

  5. Rissin, D.M. et al. Nat. Biotechnol. 28, 595–599 (2010).

    CAS  Article  Google Scholar 

  6. Randall, J. et al. Resuscitation 84, 351–356 (2013).

    CAS  Article  Google Scholar 

  7. Zetterberg, H. et al. Alzheimers Res. Ther. 5, 9 (2013).

    CAS  Article  Google Scholar 

  8. Meredith, J.E. Jr. et al. PLoS ONE 8, e76523 (2013).

    CAS  Article  Google Scholar 

  9. Kvartsberg, H. et al. Alzheimers Dement. doi:10.1016/j.jalz.2014.10.009 (19 December 2014).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kaj Blennow.

Ethics declarations

Competing interests

H.Z. and K.B. are listed as co-inventors on a US patent application (Q0052.70018US00) for plasma tau as a brain injury marker. K.B. has served on advisory boards for Eli Lilly, Kyowa Kirin Pharma, Pfizer and Roche. No other disclosures are reported.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Blennow, K., Zetterberg, H. Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding. Nat Med 21, 217–219 (2015). https://doi.org/10.1038/nm.3810

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.3810

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing